1. | We see that you present Adjusted Operating Margin, Adjusted EPS, Free Cash Flow, Adjusted Net Income and Adjusted EBITDA on the first page of your earnings release without also presenting the comparable GAAP measures with equal or greater prominence, as required by Item 10 (e)(1)(i)(A) of Regulation S-K, which is inconsistent with the updated Compliance and Disclosure Interpretations issued on May 17, 2016. Please review that guidance when preparing future earnings releases. |
2. | We see you present the non-GAAP measure Free Cash Flows in the highlights section of your earnings release without also presenting the comparable GAAP measures with equal or greater prominence, which is inconsistent with Question 102.10 of the updated Compliance and Disclosure Interpretations issued on May 17, 2016. Please review that guidance when preparing future earnings releases. See also Item 10(e)(1)(i)(A) of Regulation S-K. |
3. | Revise future earnings releases to clearly define your use of the term “organic.” |
4. | We note that in Table 2 of your earnings release you reconcile segment EBITDA to segment operating income and not to net income, which is inconsistent with the guidance in Question 103.02 of the Updated Compliance and Disclosure interpretations issued on May 17, 2016. Please review that guidance when preparing your future filings and earnings releases. |
Three months ended March 31, 2016 | |||||||||
FMT | HST | FSDP | Corporate Office | Total IDEX | |||||
Operating income (loss) | $ 51,401 | $ 40,699 | $ 25,404 | $ (14,947) | $ 102,557 | ||||
Other income (expense) - net | 167 | 373 | 90 | 114 | 744 | ||||
Depreciation and amortization | 7,256 | 10,861 | 1,482 | 358 | 19,957 | ||||
EBITDA | $ 58,824 | $ 51,933 | $ 26,976 | $ (14,475) | $ 123,258 | ||||
Interest expense | (10,489) | ||||||||
Provision for income taxes | (24,682) | ||||||||
Depreciation and amortization | (19,957) | ||||||||
Net income | $ 68,130 | ||||||||
Net sales (eliminations) | $ 211,843 | $ 186,343 | $ 104,618 | $ (232) | $ 502,572 | ||||
EBITDA margin | 27.8 % | 27.9 % | 25.8 % | n/m | 24.5 % |
5. | Please refer to the table presented on the final page of your earnings release. In future earnings releases provide a reconciliation of the net sales and operating income segment amounts presented in this table to the consolidated amounts in your statements of operations. |
Three Months Ended | |||
March 31, | |||
2016 | 2015 | ||
Fluid & Metering Technologies | |||
Net sales | $ 211,843 | $ 218,248 | |
Operating income | 51,401 | 55,898 | |
Operating margin | 24.3 | 25.6 | |
EBITDA | $ 58,824 | $ 63,061 | |
EBITDA margin | 27.8 | 28.9 | |
Depreciation and amortization | $ 7,256 | $ 6,361 | |
Capital expenditures | 3,290 | 4,969 | |
Health & Science Technologies | |||
Net sales | $ 186,343 | $ 179,120 | |
Operating income | 40,699 | 37,457 | |
Operating margin | 21.8 | 20.9 | |
EBITDA | $ 51,933 | $ 47,796 | |
EBITDA margin | 27.9 | 26.7 | |
Depreciation and amortization | $ 10,861 | $ 10,208 | |
Capital expenditures | 4,137 | 2,885 | |
Fire & Safety/Diversified Products | |||
Net sales | $ 104,618 | $ 106,622 | |
Operating income | 25,404 | 27,162 | |
Operating margin | 24.3 | 25.5 | |
EBITDA | $ 26,976 | $ 29,556 | |
EBITDA margin | 25.8 | 27.7 | |
Depreciation and amortization | $ 1,482 | $ 1,532 | |
Capital expenditures | 1,107 | 1,322 | |
Corporate office and other | |||
Intersegment sales eliminations | $ (232) | $ (1,792) | |
Operating income (loss) | (14,947) | (18,760) | |
EBITDA | (14,475) | (18,423) | |
Depreciation and amortization | 358 | 409 | |
Capital expenditures | 116 | 901 | |
Company | |||
Net sales | $ 502,572 | $ 502,198 | |
Operating income | 102,557 | 101,757 | |
Operating margin | 20.4 | 20.3 | |
EBITDA | $ 123,258 | $ 121,990 | |
EBITDA margin | 24.5 | 24.3 | |
Depreciation and amortization | $ 19,957 | $ 18,510 | |
Capital expenditures | 8,650 | 10,077 |
• | The Company is responsible for the adequacy and accuracy of the disclosure in the filings; |
• | Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and |
• | The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |